

Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19

**Martha K. Berg
Qinggang Yu
Cristina E. Salvador
Irene Melani
Shinobu Kitayama**

University of Michigan

May 14, 2020

The current analysis is based on data through May 13, 2020. This is the third biweekly update to our paper, which originally included data through April 1, 2020. It will continue to be updated every two weeks and made available at MedRxiv (<https://www.medrxiv.org/>). Address correspondence to Martha Berg or Shinobu Kitayama at Department of Psychology, University of Michigan, Ann Arbor, MI 48109 USA. Emails: bergmk@umich.edu and kitayama@umich.edu.

One sentence summary

The presence of national policies for universal BCG vaccination is associated with flattened growth curves for confirmed cases of COVID-19 infection and resulting deaths in the first 30-day period of country-wise outbreaks.

Abstract

BCG vaccination may reduce the risk of a range of infectious diseases, and, if so, could serve as a protective factor against COVID-19. Here, we compared countries that mandated BCG vaccination at least until 2000 with to countries that did not (129 countries in total). To minimize any systematic effects of reporting biases, we analyzed the rate of the day-by-day increase in both confirmed cases and deaths in the first 30-day period of country-wise outbreaks. The 30-day window was adjusted to begin at the country-wise onset of the pandemic. Linear mixed models revealed a significant effect of mandated BCG policies on the growth rate of both cases and deaths after controlling for median age, gross domestic product per capita, population density, population size, net migration rate, and various cultural dimensions (e.g., individualism and the tightness vs. looseness of social norms). Our analysis suggests that mandated BCG vaccination can be effective in the fight against COVID-19.

Introduction

The current pandemic of COVID-19 began in December 2019 in Wuhan, China. Since then, it has rapidly spread across the globe. Currently, there is no end in sight. The present work is motivated by prior evidence that *Bacillus Calmette-Guérin* (BCG) vaccination (typically given at birth and/or during childhood) offers a long-lasting protective effect not only against tuberculosis (the intended target of BCG), but also against various other infectious diseases (1–3). Recent suggestions abound that BCG could be an effective tool in fighting against COVID-19. However, existing cross-national analyses are hampered by methodological weaknesses. For the most part, no effort has been made to exclude potential effects of reporting biases. The potential benefit of universal BCG policies requires careful assessment. To address this gap, we focused on the *rate of the increase* in both confirmed cases and deaths during an early period of country-wise outbreaks, and tested whether this rate might be slower in countries that mandated BCG vaccination at least until 2000, compared to those that did not.

The BCG vaccine is used against tuberculosis (4). One review has found that BCG vaccination reduces the risk of tuberculosis by 50% (5). A follow-up of an earlier BCG clinical trial performed on native Americans show that BCG protects people from both tuberculosis and lung cancer for up to several decades, throughout each person's life (2, 3). A more recent meta-analysis of a broader range of observational studies and clinical trials (1) suggests that the effectiveness of BCG could extend to all-cause mortality. Several controlled trials provide consistent results, showing that the reduced mortality is attributable to protection against respiratory infections, as well as neonatal sepsis (6–8). Altogether, the available evidence suggests that BCG has beneficial effects on immunity against a range of lung-related infections that go beyond tuberculosis, which makes it a promising candidate for defending against COVID-19. As for mechanisms, recent experimental work (9) finds that BCG vaccination causes genome-wide epigenetic reprogramming of human monocytes, which in turn predicts protection against experimental viral infection.

Over the last century, many countries adopted universal policies of mandatory BCG vaccination to fight against tuberculosis, which was then a major threat. Since then, many countries maintained such a policy at least until very recently (e.g., China, Ireland, Finland, and France). Some other countries terminated the policies as tuberculosis ceased to be a threat (e.g., Australia, Spain, Ecuador). Of note, some countries never mandated BCG vaccination (e.g., U.S., Italy, and Lebanon). Therefore, there is sufficient variability in the presence or absence of such policies distributed across different regions of the world, which makes it possible to draw a systematic comparison.

We examined the day-by-day increase of both confirmed cases and deaths and compared the rate of increase between countries with mandated BCG policies and those without. The start of the growth curves was set to be equal across countries, thereby controlling for the varying onset of the pandemic in different countries. Specifically, we focused on a time period either after the first 100 confirmed cases (as in 12) or after one confirmed COVID-caused death. We then tested the initial, exponential spread of the virus. To exclude any systematic influences of cross-national variation in reporting biases, we focused on the rate of increase of both cases and deaths. These rates are uncontaminated by reporting biases as long as the biases are stable during the period tested. Thus, to avoid any systematic variations in reporting biases, it is important to examine a short initial period of growth. At the same time, it is necessary to test a sufficiently long period to obtain reliable estimates of the growth rate. To simultaneously meet these two competing demands, we chose to examine the first 30 days of the onset of country-wise outbreaks in the main analysis, which was followed by a robustness check testing an even shorter 15-day period. In addition, in a subsequent analysis, we adopted a measure of country-wise reporting biases and weighted the data accordingly.

We first tested whether the growth rate would be significantly slower in countries that have continued to mandate BCG vaccination at least until the year 2000, as compared to countries that do not currently require it. This year (2000) was chosen since vaccination may become effective at the population level only when a vast majority is made resistant against a target virus, a phenomenon known as “herd immunity” (11). In the countries that had mandated BCG at birth at least until the year 2000, a vary majority of adults must have been made resistant against lung-related viral infections. We also explored whether there might be any difference between those that never had such a policy and those that had one during the 20th century but have since terminated the policy for at least a few decades. As a final robustness check, we tested whether the groups of countries that vary in BCG policy status might also vary on various cultural dimensions, such as individualism vs. collectivism (13, 14) and the tightness vs. looseness of social norms (12).

Results

Confirmed Cases

All countries that had reported at least 15 days of at least 100 total confirmed cases, and that had available data on BCG policy and covariates (median age, gross domestic product per capita, population density, population size, and net migration rate) were included (118 countries in total). For each country, day 1 was set to be the first day of at least 100 confirmed cases. See Column 2 of Table S1 for the date of day 1 for each included country.

To model exponential growth of confirmed cases, we estimated a linear mixed model of the natural log-transformed number of confirmed cases. We entered two contrasts designating BCG policy status (current vs. [past and none] combined and past vs. none). The effect of BCG policy status on growth rate is reflected by the interactions between day and each BCG policy status contrast.

As shown in Table 1-A, we found a significant main effect of day, $b = 0.119$, $p < .001$, reflecting an exponential increase in cases over time. This increase was qualified by a significant interaction between day and BCG policy status. Specifically, the growth rate of COVID-19 cases was significantly slower in countries with mandated BCG vaccinations, compared to countries without mandated BCG vaccinations, $b = -0.040$, $p < .001$ (see Fig. 1-A and B).¹ Fig. 2-A shows the distribution of the country-wise regression coefficients.

Countries that once had such policies but terminated them before 2000 were not significantly different in growth rate from those that never instituted mandatory BCG vaccinations, $b = -0.014$, $p = .406$. In terms of control variables, larger population size, higher GDP per capita, and higher median age predicted a faster growth rate of confirmed cases.

The effect of BCG policy status on COVID-19 cases remained unchanged when countries were weighted by reporting quality (see Supplementary Results 1). Hence, biases in reporting, demonstrably pervasive across countries, had little or no effect on the effect of universal BCG policies on the growth rate. Moreover, this effect also did not change when a 15-day time window was used (see Supplementary Results 2-A), adding further evidence that the main analysis is unlikely to be due to any systematic variations in reporting biases during the 30-day period. In addition, the BCG effect had little to do with the cultural dimensions of individualism vs. collectivism, power distance, and tightness/looseness (see Supplementary Results 3-A).

Deaths

¹The main effect of the current BCG policy contrast in each analysis shows that there are fewer total cases and deaths in BCG-mandated countries, compared to those that do not currently mandate BCG vaccination. However, this is a necessary consequence of the rate of increase being more gradual in the former than in the latter.

All countries that had reported at least 15 days of at least one death from COVID-19, and that had available data on BCG policy and covariates (129 countries in total) were included in this analysis. For each country, day 1 was set to be the first day of at least 1 confirmed death. See column 3 of Table S1 for the date of day 1 for each included country.

We estimated a linear mixed model of the natural log-transformed number of deaths, controlling for the same control variables as above. As in the analysis on confirmed cases, we found a significant main effect of day, $b = 0.148$, $p < .001$, reflecting an exponential increase in deaths over time (Table 1-B). This increase was qualified by a significant interaction between day and BCG policy status. Specifically, the growth rate of COVID-19 related deaths was significantly less in countries with mandated BCG vaccinations, compared to countries without mandated BCG vaccinations, $b = -0.058$, $p < .001$ (Fig. 1-C and D). Fig. 2-B shows the distribution of the country-wise regression coefficients.

Countries that once had such policies but terminated them before 2000 were no different in growth rate from those that never instituted mandatory BCG, $b = -0.014$, $p = .568$. In terms of control variables, larger population size and higher median age predicted a faster growth rate of COVID-19 deaths. Greater population density predicted a slower growth rate of deaths; however, this finding should be interpreted with caution given that the spread of COVID-19 is likely influenced by population density at a more fine-grained level of analysis (e.g., cities), rather than the averaged density at the country level (13).

The effect of BCG policy status on COVID-19 related deaths remained unchanged when a 15-day time window was used (see Supplementary Results 2-B), showing the robustness of the main analysis. In addition, the BCG effect was unrelated to the cultural dimensions mentioned above (Supplementary Results 3-B).

Discussion

Our analysis shows that mandatory BCG vaccination is associated with a flattening of the curve in the spread of COVID-19. The effect we demonstrate is quite substantial.² For example, our model estimates that the total number of COVID-19 related deaths in the US as of March 29, 2020 would have been 595—24% of the actual figure (2467)—if the US had instituted the mandatory BCG vaccination several decades earlier (see Supplementary Results 5).

Our study is not the first to test the hypothesis that the country-wise spread of COVID-19 might depend on each country's BCG policy status. However, existing analyses are hampered by their focus on the cumulative totals of confirmed cases and deaths (14–28). These tallies depend on how earlier or sooner the onset of the pandemic was in each country. Moreover, they are massively influenced by reporting biases (including the availability of diagnostic testing), which can be both sizable and variable across countries. The same reservation applies to fatality rate (total deaths/total cases) (17, 25, 27–31) since the reporting biases are far more likely and cross-nationally variable for the confirmed cases than for the deaths. We circumvented these problems in two ways. First, we focused on the rate of growth of both cases and deaths, which should be uninfluenced by reporting biases as long as these biases are stable during the period of study. To meet this requirement, we focused on a short period (either

²Looking at the average slopes and standard deviations in each of the two groups of interest (BCG beyond 2000 vs. all others), the effect size is quite large (for both cases and deaths, Cohen's $d > 1.4$). However, the variance associated with the estimation of random slopes turned out quite sizable. Once taken in to account, this variance reduced the effect size dramatically (for cases and deaths, Cohen's $d = .05-.06$). Nevertheless, as we illustrate in our model prediction for the US, the practical consequences of the effect are quite significant in terms of the number of deaths that could have been avoided with mandated BCG.

the first 30 days or 15 days). Second, we used the best available estimate of country-wise reporting biases and used this as a weight in our analysis.³

Notably, the growth curves were as steep in countries that mandated BCG policies only during the 20th century as in those that never mandated the vaccine. BCG vaccination may become effective only when a substantial proportion of the population is made resistant to a virus. That is to say, the spread of the virus may be slowed only when there is “herd immunity” that prevents the virus from spreading easily across the population (see a simulation in (33)). Note that as long as others receive vaccination, any single individual will be protected without vaccination, leading to a temptation for free-riding (i.e., not getting vaccinated). Hence, in the absence of state-imposed mandatory vaccination, cultural norms emphasizing prosocial interdependent orientations (34, 35) may prove to be crucial for the success of BCG in preventing future outbreaks of COVID-19 (33, 36). While the current analysis provided no evidence, this possibility must be addressed in future work.

Some limitations of our effort must be acknowledged. In all national policies, BCG is given early in life, typically at birth. It remains unclear whether BCG vaccination might be effective when given to adults. Nor is it known how long BCG vaccination might provide immunity to COVID-19 although it is effective against tuberculosis and lung cancer for several decades (2, 3). Moreover, it is uncertain whether BCG might have any adverse effects when given to those already infected with COVID-19. There is an urgent need for randomized clinical trials. Lastly, the rates of exponential growth showed substantial variability across countries that have mandated BCG vaccination (Fig. 2-A and B). Hence, BCG is by no means a magic bullet that assures safety against COVID-19. In all likelihood, there are some societal variables that moderate this effect. This variation must be addressed in future work.

All these limitations notwithstanding, the current evidence is the first to show a significant advantage of universal BCG policies in reducing the spread of COVID-19, thereby justifying a thorough investigation of the merit of the mandatory BCG vaccination in the fight against COVID-19.

³ We engaged in a thorough review of unpublished papers on the topic on a medical preprint server (medRxiv) and identified 20 relevant papers. As noted in the text, most papers focus exclusively on total number of cases or deaths (14–28). Notably, three studies attempted something that is akin to the growth rate. One study (32) tested the amount of time required to double the number of cases and deaths. However, this study only included a total of 57 countries, and results may have been skewed by their exclusion of less populated countries. Another study (25) examined classified the countries into three categories, depending on the growth rate. But by categorizing the continuous information, this analysis ignores a huge amount of information, and moreover, the results are likely to depend on the cutoff points in the categorization. A third study (14) examined daily increases, by taking the maximum daily increase after averaging each 2-week interval; however, this method fails to account for the exponential growth of COVID-19 that is expected in the first few weeks of an outbreak.

References

1. J. P. T. Higgins, K. Soares-Weiser, J. A. López-López, A. Kakourou, K. Chaplin, H. Christensen, N. K. Martin, J. A. C. Sterne, A. L. Reingold, Association of BCG, DTP, and measles containing vaccines with childhood mortality: Systematic review. *BMJ*, i5170 (2016).
2. N. E. Aronson, M. Santosham, G. W. Comstock, R. S. Howard, L. H. Moulton, E. R. Rhoades, L. H. Harrison, Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. *JAMA*. **291**, 2086 (2004).
3. N. T. Usher, S. Chang, R. S. Howard, A. Martinez, L. H. Harrison, M. Santosham, N. E. Aronson, Association of BCG vaccination in childhood with subsequent cancer diagnoses: A 60-year follow-up of a clinical trial. *JAMA Netw Open*. **2**, e1912014 (2019).
4. World Health Organization, BCG vaccines: WHO position paper – February 2018. *Weekly Epidemiological Record*. **93**, 73–96 (2018).
5. G. A. Colditz, Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. *JAMA*. **271**, 698 (1994).
6. P. Aaby, A. Roth, H. Ravn, B. M. Napirna, A. Rodrigues, I. M. Lisse, L. Stensballe, B. R. Diness, K. R. Lausch, N. Lund, S. Biering-Sørensen, H. Whittle, C. S. Benn, Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial nonspecific effects in the neonatal period? *The Journal of Infectious Diseases*. **204**, 245–252 (2011).
7. A. Roth, H. Jensen, M.-L. Garly, Q. Djana, C. L. Martins, M. Sodemann, A. Rodrigues, P. Aaby, Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau. *Pediatr. Infect. Dis. J.* **23**, 544–550 (2004).
8. S. Biering-Sørensen, P. Aaby, B. M. Napirna, A. Roth, H. Ravn, A. Rodrigues, H. Whittle, C. S. Benn, Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. *Pediatr. Infect. Dis. J.* **31**, 306–308 (2012).
9. R. J. W. Arts, S. J. C. F. M. Moorlag, B. Novakovic, Y. Li, S.-Y. Wang, M. Oosting, V. Kumar, R. J. Xavier, C. Wijmenga, L. A. B. Joosten, C. B. E. M. Reusken, C. S. Benn, P. Aaby, M. P. Koopmans, H. G. Stunnenberg, R. van Crevel, M. G. Netea, BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. *Cell Host & Microbe*. **23**, 89-100.e5 (2018).
10. M. Roser, H. Ritchie, E. Ortiz-Ospina, Coronavirus disease (COVID-19) – Statistics and research. *Our World in Data* (2020) (available at <https://ourworldindata.org/coronavirus>).
11. R. M. Anderson, R. M. May, Vaccination and herd immunity to infectious diseases. *Nature*. **318**, 323–329 (1985).
12. M. J. Gelfand, J. L. Raver, L. Nishii, L. M. Leslie, J. Lun, B. C. Lim, L. Duan, A. Almaliach, S. Ang, J. Arnadottir, Z. Aycan, K. Boehnke, P. Boski, R. Cabecinhas, D. Chan, J. Chhokar, A. D'Amato, M. Ferrer, I. C. Fischlmayr, R. Fischer, M. Fulop, J. Georgas, E. S. Kashima, Y. Kashima, K. Kim, A. Lempereur, P. Marquez, R. Othman, B. Overlaet, P.

- Panagiotopoulou, K. Peltzer, L. R. Perez-Florizno, L. Ponomarenko, A. Realo, V. Schei, M. Schmitt, P. B. Smith, N. Soomro, E. Szabo, N. Taveesin, M. Toyama, E. Van de Vliert, N. Vohra, C. Ward, S. Yamaguchi, Differences between tight and loose cultures: A 33-nation study. *Science*. **332**, 1100–1104 (2011).
13. Q. Yu, C. Salvador, I. Melani, M. Berg, S. Kitayama, The lethal spiral: Racial segregation and economic disparity jointly exacerbate the COVID-19 fatality in large American cities. (preprint, PsyArXiv, 2020), doi:10.31234/osf.io/xgbpy.
 14. M. Asahara, The effect of BCG vaccination on COVID-19 examined by a statistical approach: no positive results from the Diamond Princess and cross-national differences previously reported by world-wide comparisons are flawed in several ways. (preprint, medRxiv, 2020), doi:10.1101/2020.04.17.20068601.
 15. S. Dolgikh, Further evidence of a possible correlation between the severity of COVID-19 and BCG immunization. (preprint, medRxiv, 2020), doi:10.1101/2020.04.07.20056994.
 16. M. Fukui, K. Kawaguchi, H. Matsuura, Does TB vaccination reduce COVID-19 infection?: No evidence from a regression discontinuity analysis (preprint, medRxiv, 2020), doi:10.1101/2020.04.13.20064287.
 17. R. P. Goswami, D. K. Mittal, R. P. Goswami, Interaction between malarial transmission and BCG vaccination with COVID-19 incidence in the world map: A changing landscape human immune system? (preprint, medRxiv, 2020), doi:10.1101/2020.04.03.20052563.
 18. C. M. Green, S. Fanucchi, E. T. Fok, S. J. C. F. M. Moorlag, J. Dominguez-Andres, Y. Negishi, L. A. B. Joosten, M. G. Netea, M. M. Mhlanga, COVID-19: A model correlating BCG vaccination to protection from mortality implicates trained immunity. (preprint, medRxiv, 2020), doi:10.1101/2020.04.10.20060905.
 19. P. K. Hegarty, A. M. Kamat, H. Zafirakis, A. Dinardo, BCG vaccination may be protective against COVID-19. (preprint, 2020), (available at https://www.researchgate.net/publication/340224580_BCG_vaccination_may_be_protective_against_Covid-19).
 20. J. Hensel, D. J. McGrail, K. M. McAndrews, D. Dowlatshahi, V. S. LeBleu, R. Kalluri, Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. (preprint, Epidemiology, 2020), doi:10.1101/2020.04.08.20056051.
 21. S. Kirov, Association between BCG policy is significantly confounded by age and is unlikely to alter infection or mortality rates. (preprint, medRxiv, 2020), doi:10.1101/2020.04.06.20055616.
 22. D. Klinger, I. Blass, N. Rappoport, M. Linial, Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis. (preprint, medRxiv, 2020), doi:10.1101/2020.04.23.20077123.
 23. A. Miller, M. J. Reandelar, K. Fasciglione, V. Roumenova, Y. Li, G. H. Otazu, Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. (preprint, 2020), doi:10.1101/2020.03.24.20042937.

24. J. A. P. Mogica, V. Nava, J. Torres, COVID-19 related mortality: Is the BCG vaccine truly effective? (preprint, medRxiv, 2020), doi:10.1101/2020.05.01.20087411.
25. G. Sala, T. Miyakawa, Association of BCG vaccination policy with prevalence and mortality of COVID-19. (preprint, medRxiv, 2020), doi:10.1101/2020.03.30.20048165.
26. A. Shet, D. Ray, N. Malavige, M. Santosham, N. Bar-Zeev, Differential COVID-19-attributable mortality and BCG vaccine use in countries. (preprint, medRxiv, 2020), doi:10.1101/2020.04.01.20049478.
27. S. Shivendu, S. Chakraborty, A. Onuchowska, A. Srivastava, A. Patidar, Is there evidence that BCG vaccination has non-specific protective effects for COVID 19 infections or is it an illusion created by lack of testing? (preprint, medRxiv, 2020), doi:10.1101/2020.04.18.20071142.
28. S. Singh, BCG vaccines may not reduce COVID-19 mortality rates. (preprint, medRxiv, 2020), doi:10.1101/2020.04.11.20062232.
29. K. Bodova, V. Boza, B. Brejova, R. Kollar, K. Mikusova, T. Vinar, Time-adjusted analysis shows weak associations between BCG vaccination policy and COVID-19 disease progression. (preprint, medRxiv, 2020), doi:10.1101/2020.05.01.20087809.
30. D. Dayal, S. Gupta, Connecting BCG vaccination and COVID-19: Additional data. (preprint, medRxiv, 2020), doi:10.1101/2020.04.07.20053272.
31. R. Szigeti, D. Kellermayer, R. Kellermayer, BCG protects against COVID-19? A word of caution. (preprint, medRxiv, 2020), doi:10.1101/2020.04.09.20056903.
32. Y. Akiyama, T. Ishida, Relationship between COVID-19 death toll doubling time and national BCG vaccination policy. (preprint, medRxiv, 2020), doi:10.1101/2020.04.06.20055251.
33. C. Betsch, R. Böhm, L. Korn, C. Holtmann, On the benefits of explaining herd immunity in vaccine advocacy. *Nat Hum Behav.* **1**, 0056 (2017).
34. H. R. Markus, S. Kitayama, Culture and the self: Implications for cognition, emotion, and motivation. *Psychological Review.* **98**, 224–253 (1991).
35. S. Kitayama, J. Park, Error-related brain activity reveals self-centric motivation: Culture matters. *Journal of Experimental Psychology: General.* **143**, 62–70 (2014).
36. D. Brockmann, Public health: This message must be herd. *Nat Hum Behav.* **1**, 0065 (2017).

Table 1. Regression tables predicting growth in (A) cases and (B) deaths. Day is mean centered, and BCG policy variables are both contrast-coded. Population is natural log-transformed, and all covariates are standardized.

Predictor	A. Cases				B. Deaths			
	b	t	p		b	t	p	
Intercept	6.918	301.690	<.001	***	2.620	72.234	<.001	***
Day	0.119	19.110	<.001	***	0.148	16.259	<.001	***
Median age	0.390	24.863	<.001	***	0.489	20.589	<.001	***
GDP per capita	0.156	7.097	<.001	***	0.150	4.572	<.001	***
Population density	-0.168	-14.052	<.001	***	-0.152	-8.445	<.001	***
Net migration rate	0.111	5.887	<.001	***	0.017	0.571	0.568	
Population	0.519	40.718	<.001	***	0.546	29.715	<.001	***
BCG past vs. never	0.115	1.836	0.066	+	-0.203	-2.053	0.040	*
BCG current vs. not current	-0.624	-16.876	<.001	***	-0.941	-16.135	<.001	***
Day x median age	0.017	4.050	<.001	***	0.032	5.428	<.001	***
Day x GDP per capita	0.012	2.055	0.042	*	0.011	1.288	0.200	
Day x population density	-0.006	-1.763	0.081	+	-0.011	-2.389	0.018	*
Day x net migration rate	0.003	0.674	0.502		0.002	0.224	0.823	
Day x population	0.032	9.420	<.001	***	0.030	6.581	<.001	***
Day x BCG past vs. never	-0.014	-0.835	0.406		-0.014	-0.573	0.568	
Day x BCG current vs. not current	-0.040	-3.945	<.001	***	-0.058	-3.930	<.001	***

Figure 1. Growth curves by country BCG policy for (A-B) cases and (C-D) deaths, presented on linear (A & C) and logarithmic (B & D) scales.




Figure 2. Growth rate of (A) cases and (B) deaths for each country, plotted by BCG policy and region. Growth rate is adjusted by median age, GDP per capita, population density, total population (log-transformed), and net migration rate. Means and standard error are plotted for each group.

